UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 66

Sortiert nach

Virus Susceptibility Analyses from a Phase IV Clinical Trial of Inhaled Zanamivir Treatment in Children Infected with Influenza

Antimicrobial Agents and Chemotherapy, 2013-04, Vol.57 (4), p.1677-1684

2013

Link zum Volltext

Verfügbarkeit prüfen

Changes in Human Immunodeficiency Virus Type 1 Gag at Positions L449 and P453 Are Linked to I50V Protease Mutants In Vivo and Cause Reduction of Sensitivity to Amprenavir and Improved Viral Fitness In Vitro

Journal of Virology, 2002-08, Vol.76 (15), p.7398-7406

2002

Link zum Volltext

Verfügbarkeit prüfen

Resistance Profile of the Human Immunodeficiency Virus Type 1 Reverse Transcriptase Inhibitor Abacavir (1592U89) after Monotherapy and Combination Therapy

The Journal of infectious diseases, 2000-03, Vol.181 (3), p.912-920

2000

Link zum Volltext

Verfügbarkeit prüfen

Emergence of Resistance to Protease Inhibitor Amprenavir in Human Immunodeficiency Virus Type 1-Infected Patients: Selection of Four Alternative Viral Protease Genotypes and Influence of Viral Susceptibility to Coadministered Reverse Transcriptase Nucleoside Inhibitors

Antimicrobial Agents and Chemotherapy, 2002-03, Vol.46 (3), p.731-738

2002

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and Safety of Inhaled Zanamivir in the Prevention of Influenza in Community-Dwelling, High-Risk Adult and Adolescent Subjects: A 28-day, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial

Clinical therapeutics, 2007-08, Vol.29 (8), p.1579-1590

2007

Link zum Volltext

Verfügbarkeit prüfen

Human Immunodeficiency Virus Type 1 Reverse Transcriptase Mutation Selection during In Vitro Exposure to Tenofovir Alone or Combined with Abacavir or Lamivudine

Antimicrobial Agents and Chemotherapy, 2004-04, Vol.48 (4), p.1413-1415

2004

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of Zanamivir against Avian Influenza A Viruses That Possess Genes Encoding H5N1 Internal Proteins and Are Pathogenic in Mammals

Antimicrobial Agents and Chemotherapy, 2001-04, Vol.45 (4), p.1216-1224

2001

Link zum Volltext

Verfügbarkeit prüfen

Monitoring of viral susceptibility: new challenges with the development of influenza NA inhibitors

Reviews in medical virology, 2000-01, Vol.10 (1), p.45-55

Tisdale, Margaret

2000

Link zum Volltext

Verfügbarkeit prüfen

HIV type 1 protease cleavage site mutations and viral fitness : Implications for drug susceptibility phenotyping assays

AIDS research and human retroviruses, 2000-08, Vol.16 (12), p.1149-1156

2000

Link zum Volltext

Verfügbarkeit prüfen

Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89

Antimicrobial Agents and Chemotherapy, 1997-05, Vol.41 (5), p.1094-1098

1997

Link zum Volltext

Verfügbarkeit prüfen

Mutations conferring zanamivir resistance in human influenza virus N2 neuraminidases compromise virus fitness and are not stably maintained in vitro

Journal of antimicrobial chemotherapy, 2006-10, Vol.58 (4), p.723-732

2006

Link zum Volltext

Verfügbarkeit prüfen

1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity

Antimicrobial Agents and Chemotherapy, 1997-05, Vol.41 (5), p.1082-1093

1997

Link zum Volltext

Verfügbarkeit prüfen

Rapid in vitro Selection of Human Immunodeficiency Virus Type 1 Resistant to 3'-Thiacytidine Inhibitors Due to a Mutation in the YMDD Region of Reverse Transcriptase

Proceedings of the National Academy of Sciences - PNAS, 1993-06, Vol.90 (12), p.5653-5656

1993

Link zum Volltext

Verfügbarkeit prüfen

Phenotypic impact of HIV reverse transcriptase M184I/V mutations in combination with single thymidine analog mutations on nucleoside reverse transcriptase inhibitor resistance

AIDS (London), 2004-08, Vol.18 (12), p.1691-1696

2004

Link zum Volltext

Verfügbarkeit prüfen

HIV-1 reverse transcriptase (RT) genotype and susceptibility to RT inhibitors during abacavir monotherapy and combination therapy

AIDS (London), 2000-01, Vol.14 (2), p.163-171

2000

Link zum Volltext

Verfügbarkeit prüfen

Development of a Sensitive Chemiluminescent Neuraminidase Assay for the Determination of Influenza Virus Susceptibility to Zanamivir

Analytical biochemistry, 2000-05, Vol.280 (2), p.291-300

2000

Link zum Volltext

Verfügbarkeit prüfen

Human Immunodeficiency Virus

The Journal of biological chemistry, 1996-12, Vol.271 (52), p.33231-33235

1996

Link zum Volltext

Verfügbarkeit prüfen

M184V is associated with a low incidence of thymidine analogue mutations and low phenotypic resistance to zidovudine and stavudine

AIDS (London), 2002-08, Vol.16 (12), p.1686-1689

2002

Link zum Volltext

Verfügbarkeit prüfen

Human immunodeficiency virus. Mutations in the viral protease that confer resistance to saquinavir increase the dissociation rate constant of the protease-saquinavir complex

The Journal of biological chemistry, 1996-12, Vol.271 (52), p.33231-33235

1996

Link zum Volltext

Verfügbarkeit prüfen

Characterization of 2 Influenza A(H3N2) Clinical Isolates with Reduced Susceptibility to Neuraminidase Inhibitors Due to Mutations in the Hemagglutinin Gene

The Journal of infectious diseases, 2002-10, Vol.186 (8), p.1074-1080

2002

Link zum Volltext

Verfügbarkeit prüfen

In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease

Journal of Virology, 1995-09, Vol.69 (9), p.5228-5235

1995

Link zum Volltext

Verfügbarkeit prüfen

Absence of zidovudine resistance in antiretroviral-naive patients following zidovudine/lamivudine/protease inhibitor combination therapy : virological evaluation of the AVANTI 2 and AVANTI 3 studies

AIDS (London), 2000-06, Vol.14 (9), p.1195-1201

2000

Link zum Volltext

Verfügbarkeit prüfen

Differentiation of genotypic resistance profiles for amprenavir and lopinavir, a valuable aid for choice of therapy in protease inhibitor-experienced HIV-1-infected subjects

Journal of antimicrobial chemotherapy, 2003-09, Vol.52 (3), p.319-323

2003

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of inhaled zanamivir in the prevention of influenza in community-dwelling, high-risk adult and adolescent subjects : A 28-day, multicenter, randomized, double-blind, placebo-controlled trial

Clinical therapeutics, 2007, Vol.29 (8), p.1577-1590

2007

Link zum Volltext

Verfügbarkeit prüfen

HIV-1 reverse transcriptase and protease resistance mutations selected during 16-72 weeks of therapy in isolates from antiretroviral therapy-experienced patients receiving abacavir/efavirenz/amprenavir in the cna2007 study

Antiviral therapy, 2003-04, Vol.8 (2), p.111-120

2003

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 66

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(63)
Mit Volltextzugriff
(59)

Publikationsform

Artikel
(64)
Dissertationen
(2)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(48)
Life Sciences & Biomedicine
(41)
Humans
(34)
Biological And Medical Sciences
(30)
Medical Sciences
(24)
Infectious Diseases
(21)
Pharmacology. Drug Treatments
(20)
Antibiotics. Antiinfectious Agents. Antiparasitic Agents
(19)
Antiviral Agents
(19)
Virology
(19)
Microbiology
(17)
Pharmacology & Pharmacy
(16)
Aids/hiv
(15)
Female
(14)
Hiv-1 - Drug Effects
(13)
Mutation
(12)
Adult
(11)
Genotype
(11)
Human Immunodeficiency Virus 1
(11)
Animals
(9)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Virus Susceptibility Analyses from a Phase IV Clinical Trial of Inhaled Zanamivir Treatment in Children Infected with Influenza

Changes in Human Immunodeficiency Virus Type 1 Gag at Positions L449 and P453 Are Linked to I50V Protease Mutants In Vivo and Cause Reduction of Sensitivity to Amprenavir and Improved Viral Fitness In Vitro

Resistance Profile of the Human Immunodeficiency Virus Type 1 Reverse Transcriptase Inhibitor Abacavir (1592U89) after Monotherapy and Combination Therapy

Emergence of Resistance to Protease Inhibitor Amprenavir in Human Immunodeficiency Virus Type 1-Infected Patients: Selection of Four Alternative Viral Protease Genotypes and Influence of Viral Susceptibility to Coadministered Reverse Transcriptase Nucleoside Inhibitors

Efficacy and Safety of Inhaled Zanamivir in the Prevention of Influenza in Community-Dwelling, High-Risk Adult and Adolescent Subjects: A 28-day, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial

Human Immunodeficiency Virus Type 1 Reverse Transcriptase Mutation Selection during In Vitro Exposure to Tenofovir Alone or Combined with Abacavir or Lamivudine

Efficacy of Zanamivir against Avian Influenza A Viruses That Possess Genes Encoding H5N1 Internal Proteins and Are Pathogenic in Mammals

Monitoring of viral susceptibility: new challenges with the development of influenza NA inhibitors

HIV type 1 protease cleavage site mutations and viral fitness : Implications for drug susceptibility phenotyping assays

Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89

Mutations conferring zanamivir resistance in human influenza virus N2 neuraminidases compromise virus fitness and are not stably maintained in vitro

1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity

Rapid in vitro Selection of Human Immunodeficiency Virus Type 1 Resistant to 3'-Thiacytidine Inhibitors Due to a Mutation in the YMDD Region of Reverse Transcriptase

Phenotypic impact of HIV reverse transcriptase M184I/V mutations in combination with single thymidine analog mutations on nucleoside reverse transcriptase inhibitor resistance

HIV-1 reverse transcriptase (RT) genotype and susceptibility to RT inhibitors during abacavir monotherapy and combination therapy

Development of a Sensitive Chemiluminescent Neuraminidase Assay for the Determination of Influenza Virus Susceptibility to Zanamivir

Human Immunodeficiency Virus

M184V is associated with a low incidence of thymidine analogue mutations and low phenotypic resistance to zidovudine and stavudine

Human immunodeficiency virus. Mutations in the viral protease that confer resistance to saquinavir increase the dissociation rate constant of the protease-saquinavir complex

Characterization of 2 Influenza A(H3N2) Clinical Isolates with Reduced Susceptibility to Neuraminidase Inhibitors Due to Mutations in the Hemagglutinin Gene

In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease

Absence of zidovudine resistance in antiretroviral-naive patients following zidovudine/lamivudine/protease inhibitor combination therapy : virological evaluation of the AVANTI 2 and AVANTI 3 studies

Differentiation of genotypic resistance profiles for amprenavir and lopinavir, a valuable aid for choice of therapy in protease inhibitor-experienced HIV-1-infected subjects

Efficacy and safety of inhaled zanamivir in the prevention of influenza in community-dwelling, high-risk adult and adolescent subjects : A 28-day, multicenter, randomized, double-blind, placebo-controlled trial

HIV-1 reverse transcriptase and protease resistance mutations selected during 16-72 weeks of therapy in isolates from antiretroviral therapy-experienced patients receiving abacavir/efavirenz/amprenavir in the cna2007 study

Suchergebnisse filtern